Diese Seite wurde automatisch übersetzt und die Genauigkeit der Übersetzung wird nicht garantiert. Bitte wende dich an die englische Version für einen Quelltext.

Independent and Combined Effects of Short-term Sulforaphane Supplementation and Exercise on Immunometabolism in Healthy Adults (EXSFN)

19. Juni 2026 aktualisiert von: Hashim Islam, University of British Columbia

Independent and Combined Effects of Short-term Sulforaphane Supplementation and Exercise on Immunometabolism in Healthy Adults: A Randomized Crossover Study

The study consist of 3 interventional periods which will be completed by each consenting participant in a randomized, crossover fashion. The interventional periods will be separated by a minimum 1 week washout period. One of the interventions consists of 4 days of daily supplementation with the commercially available broccoli sprout extract capsules (BrocElite). Another intervention will consist of 4 days of daily supervised treadmill running. The exercise protocol consists of 4 minutes of high-intensity running running followed by a 3 minute recovery period, repeated for a total of 4 repetitions. The last intervention combines the above two and consists of 4 days of daily supplementation and daily supervised exercise training. Before and after each intervention, basic anthropometrics (weight, heart rate, and blood pressure) will be recorded, and a venous blood sample will be collected. Blood samples will be analyzed for metabolic and inflammatory markers. Participants will be asked to refrain from structured exercise, alcohol consumption, and broccoli consumption during each of the experimental periods. Before any testing, willing participants will provide informed consent, and fill out a few demographic, and lifestyle questionnaires. The study will be conducted at the University of British Columbia in Kelowna, BC, Canada.

Studienübersicht

Studientyp

Interventionell

Einschreibung (Geschätzt)

20

Phase

  • Unzutreffend

Kontakte und Standorte

Dieser Abschnitt enthält die Kontaktdaten derjenigen, die die Studie durchführen, und Informationen darüber, wo diese Studie durchgeführt wird.

Studienkontakt

  • Name: Hashim Islam Principle Investigator, Ph.D
  • Telefonnummer: 250-807-9122
  • E-Mail: hashim.islam@ubc.ca

Studienorte

    • British Columbia
      • Kelowna, British Columbia, Kanada, V1V 1V7
        • Rekrutierung
        • Reichwald Health Sciences Centre
        • Kontakt:

Teilnahmekriterien

Forscher suchen nach Personen, die einer bestimmten Beschreibung entsprechen, die als Auswahlkriterien bezeichnet werden. Einige Beispiele für diese Kriterien sind der allgemeine Gesundheitszustand einer Person oder frühere Behandlungen.

Zulassungskriterien

Studienberechtigtes Alter

  • Erwachsene

Akzeptiert gesunde Freiwillige

Ja

Beschreibung

Inclusion Criteria:

  • aged between 18 and 35 years
  • not a current smoker
  • physically active based on the Canadian Physical Activity Guidelines (150 minutes of weekly physical activity)

Exclusion Criteria:

  • a history of cardiometabolic diseases or respiratory diseases (e.g., chronic obstructive pulmonary disease, asthma, diabetes, coronary artery disease)
  • currently following a ketogenic diet
  • body mass index (BMI) over 30 kg/m2
  • unable to read or communicate in English
  • having received a vaccination or experienced an upper respiratory tract infection in the last 4 weeks
  • having donated more than 0.5 L of blood within the last 4 weeks
  • currently pregnant
  • have contraindications to high intensity exercise (assessed using the CSEP Get Active Questionnaire)

Studienplan

Dieser Abschnitt enthält Einzelheiten zum Studienplan, einschließlich des Studiendesigns und der Messung der Studieninhalte.

Wie ist die Studie aufgebaut?

Designdetails

  • Hauptzweck: Grundlegende Wissenschaft
  • Zuteilung: Zufällig
  • Interventionsmodell: Crossover-Aufgabe
  • Maskierung: Keine (Offenes Etikett)

Waffen und Interventionen

Teilnehmergruppe / Arm
Intervention / Behandlung
Experimental: Sulforaphane Supplementation Only
In this intervention, participants will consume commercially available broccoli sprout extract capsules daily for 4 days (20 mg/day) . Basic anthropometrics (weight, heart rate, blood pressure) and a venous blood sample (30 mL) will be collected before and after this interventional period.
Broc Elite Plus stabilized sulforaphane capsules from Mara Labs
Aktiver Komparator: Exercise Only
In this intervention, participants will complete supervised exercise sessions daily for 4 days. The exercise intervention consists of interval running on a treadmill which contains 4 cycles of: 4 minutes of intense running (85-95% HRmax) followed by 3 minutes at a slow, easy pace. Basic anthropometrics (weight, heart rate, blood pressure) and a venous blood sample (30 mL) will be collected before and after this interventional period.
4 cycles of: 4 minutes of intense treadmill running (85-95% HR max) followed by 3 minutes of slow, easy running.
Experimental: Sulforaphane Supplementation and Exercise
In this intervention, participants will consume commercially available broccoli sprout extract tablets daily for 4 days. In addition, participants will complete supervised exercise sessions daily for 4 days. The exercise intervention consists of interval running on a treadmill which contains 4 cycles of: 4 minutes of intense running (85-95% HRmax) followed by 3 minutes at a slow, easy pace. Basic anthropometrics (weight, heart rate, blood pressure) and a venous blood sample (30 mL) will be collected before and after this interventional period.
Broc Elite Plus stabilized sulforaphane capsules from Mara Labs
4 cycles of: 4 minutes of intense treadmill running (85-95% HR max) followed by 3 minutes of slow, easy running.

Was misst die Studie?

Primäre Ergebnismessungen

Ergebnis Maßnahme
Maßnahmenbeschreibung
Zeitfenster
Change in peripheral blood mononuclear cell oxygen consumption rate
Zeitfenster: 0-4 days
OCR will be measured using a Seahorse Analyzer before and after each 4-day intervention
0-4 days

Sekundäre Ergebnismessungen

Ergebnis Maßnahme
Maßnahmenbeschreibung
Zeitfenster
TNF-alpha secretion from LPS-stimulated whole blood
Zeitfenster: 0-4 days
TNF-alpha secretion from LPS-stimulated whole blood will be measured via ELISA before and after each 4-day period
0-4 days
Change in % of classical monocytes before and after the 6-week intervention
Zeitfenster: 0-4 days
The % of classical monocytes will be measured using flow cytometry at baseline and after the 4-day intervention
0-4 days
Change in % of intermediate monocytes before and after the 4-day intervention
Zeitfenster: 0-4 days
The % of intermediate monocytes will be measured using flow cytometry at baseline and after the 4-day intervention
0-4 days
Change in % of non-classical monocytes before and after the 4-day intervention
Zeitfenster: 0-4 days
The % of non-classical monocytes will be measured using flow cytometry at baseline and after the 4-day intervention
0-4 days
Change in TLR-4 expression on classical monocytes before and after the 4-day intervention
Zeitfenster: 0-4 days
TLR-4 expression on classical monocytes will be measured using flow cytometry at baseline and after the 4-day intervention.
0-4 days
Change in TLR-4 expression on intermediate monocytes before and after the 4-day intervention
Zeitfenster: 0-4 days
TLR-4 expression on intermediate monocytes will be measured using flow cytometry at baseline and after the 4-day intervention.
0-4 days
Change in TLR-4 expression on non-classical monocytes before and after the 4-day intervention
Zeitfenster: 0-4 days
TLR-4 expression on non-classical monocytes will be measured using flow cytometry at baseline and after the 4-day intervention
0-4 days
Change in white blood cell counts before and after the 4-day intervention
Zeitfenster: 0-4 days
White blood cell counts will be measured using a hematology analyzer at baseline and after the 4-day intervention
0-4 days
TNF-alpha secretion from PolyIC-stimulated whole blood
Zeitfenster: 0-4 days
TNF-alpha secretion from PolyIC-stimulated whole blood will be measured via ELISA before and after each 4-day period
0-4 days
Change in peripheral blood mononuclear cell extracellular acidification rate before and after the 4-day period
Zeitfenster: 0-4 days
PBMC ECAR will be measured using a Seahorse Analyzer at baseline and after the 4-day intervention
0-4 days
Change in PBMC mitotracker green staining before and after the 4-day period
Zeitfenster: 0-4 days
PBMC mitotracker green will be measured using flow cytometry before and after the 4-day intervention period
0-4 days
Change in PBMC mitoSOX red staining before and after the 4-day period
Zeitfenster: 0-4 days
PBMC mitoSOX red will be measured using flow cytometry before and after the 4-day intervention period
0-4 days
Change in PBMC mitochondrial respiration before and after the 4-day intervention period
Zeitfenster: 0-4 days
PBMC mitochondrial respiration will be measured using high-resolution respirometry before and after the 4-day period
0-4 days

Mitarbeiter und Ermittler

Hier finden Sie Personen und Organisationen, die an dieser Studie beteiligt sind.

Studienaufzeichnungsdaten

Diese Daten verfolgen den Fortschritt der Übermittlung von Studienaufzeichnungen und zusammenfassenden Ergebnissen an ClinicalTrials.gov. Studienaufzeichnungen und gemeldete Ergebnisse werden von der National Library of Medicine (NLM) überprüft, um sicherzustellen, dass sie bestimmten Qualitätskontrollstandards entsprechen, bevor sie auf der öffentlichen Website veröffentlicht werden.

Haupttermine studieren

Studienbeginn (Tatsächlich)

1. März 2026

Primärer Abschluss (Geschätzt)

1. Dezember 2027

Studienabschluss (Geschätzt)

1. Juni 2028

Studienanmeldedaten

Zuerst eingereicht

19. Juni 2026

Zuerst eingereicht, das die QC-Kriterien erfüllt hat

19. Juni 2026

Zuerst gepostet (Tatsächlich)

25. Juni 2026

Studienaufzeichnungsaktualisierungen

Letztes Update gepostet (Tatsächlich)

25. Juni 2026

Letztes eingereichtes Update, das die QC-Kriterien erfüllt

19. Juni 2026

Zuletzt verifiziert

1. Juni 2026

Mehr Informationen

Begriffe im Zusammenhang mit dieser Studie

Plan für individuelle Teilnehmerdaten (IPD)

Planen Sie, individuelle Teilnehmerdaten (IPD) zu teilen?

NEIN

Beschreibung des IPD-Plans

IPD will not be shared to ensure the privacy and confidentiality of participants, in accordance with ethical guidelines and data protection regulations. Additionally, this was not included in the informed consent, which did not cover data sharing or address potential risks of re-identification.

Arzneimittel- und Geräteinformationen, Studienunterlagen

Studiert ein von der US-amerikanischen FDA reguliertes Arzneimittelprodukt

Nein

Studiert ein von der US-amerikanischen FDA reguliertes Geräteprodukt

Nein

Diese Informationen wurden ohne Änderungen direkt von der Website clinicaltrials.gov abgerufen. Wenn Sie Ihre Studiendaten ändern, entfernen oder aktualisieren möchten, wenden Sie sich bitte an register@clinicaltrials.gov. Sobald eine Änderung auf clinicaltrials.gov implementiert wird, wird diese automatisch auch auf unserer Website aktualisiert .

Klinische Studien zur Sulforaphane-rich Broccoli Sprout Extract

3
Abonnieren